BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: BEAT
- Previous Close: $24.95
- 50 Day Moving Average: $23.15
- 200 Day Moving Average: $20.40
- 52-Week Range: $10.96 - $25.94
- Trailing P/E Ratio: 47.98
- Foreward P/E Ratio: 28.35
- P/E Growth: 1.42
- Market Cap: $704.36M
- Outstanding Shares: 28,231,000
- Beta: 0.9
- Net Margins: 7.58%
- Return on Equity: 26.70%
- Return on Assets: 15.81%
Companies Related to BioTelemetry:
- Debt-to-Equity Ratio: 0.26%
- Current Ratio: 1.60%
- Quick Ratio: 1.51%
What is BioTelemetry's stock symbol?
BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."
Where is BioTelemetry's stock going? Where will BioTelemetry's stock price be in 2017?
5 analysts have issued twelve-month price targets for BioTelemetry's shares. Their predictions range from $24.00 to $27.00. On average, they anticipate BioTelemetry's stock price to reach $25.50 in the next twelve months.
When will BioTelemetry announce their earnings?
BioTelemetry is scheduled to release their next quarterly earnings announcement on Wednesday, February, 22nd 2017.
Who owns BioTelemetry stock?
BioTelemetry's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (5.11%), Renaissance Technologies LLC (3.89%), State Street Corp (2.50%), Thompson Siegel & Walmsley LLC (2.34%), Cortina Asset Management LLC (2.01%) and Allianz Asset Management AG (1.38%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper and Peter Ferola.
Who sold BioTelemetry stock? Who is selling BioTelemetry stock?
BioTelemetry's stock was sold by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Royce & Associates LP, Allianz Asset Management AG, Two Sigma Investments LP, Bogle Investment Management L P DE, Oxford Asset Management, AQR Capital Management LLC and GSA Capital Partners LLP. Company insiders that have sold BioTelemetry stock in the last year include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper and Peter Ferola.
Who bought BioTelemetry stock? Who is buying BioTelemetry stock?
BioTelemetry's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nicholas Investment Partners LP, Ancora Advisors LLC, Renaissance Technologies LLC, Systematic Financial Management LP, Guggenheim Capital LLC, Dimensional Fund Advisors LP and A.R.T. Advisors LLC.
How do I buy BioTelemetry stock?
Shares of BioTelemetry can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BioTelemetry stock cost?
One share of BioTelemetry stock can currently be purchased for approximately $24.95.